A photo of Rebecca Marsh.

Rebecca A. Marsh, MD

  • Clinical Director, Primary Immune Deficiency Program
  • Co-Director, Diagnostic Immunology Laboratories
  • Clinical Director, HLH Center of Excellence
  • Professor, UC Department of Pediatrics
Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.
Rebecca A. Marsh, MD



I’ve always been fascinated by the immune system and also felt a calling to pediatrics. I enjoy working with people and developing long-term relationships with patients and families, so my career in primary immune deficiencies and hematopoietic cell transplantation is a perfect fit. My practice combines my love of immunology with caring for pediatric patients and working in a team-based setting.

As an immunologist and transplant physician, I treat patients with primary immune deficiencies and immune regulatory diseases, which are collectively called inborn errors of immunity. I’m the clinical director of the Primary Immune Deficiency Program and co-director of Diagnostic Immunology Laboratory.

Our practice provides a variety of treatments for patients, including allogeneic hematopoietic cell transplantation. Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.

We have a large group of specialists in the diagnosis and treatment of inborn errors of immunity. We also have the largest clinical laboratory specializing in primary immunodeficiency diagnostics. Our physician group consists of several experts in primary immunodeficiencies. Our physicians not only provide state-of-the-art treatment for patients, but they also lead the field with primary immune deficiency research and new treatment trials.

We have many nurse practitioners dedicated to caring for patients with inborn errors of immunity. Patients in our practice also work with a dedicated nurse coordinator who helps patients navigate their medical care. Our practice is special because we provide cutting-edge diagnostics and treatments for our patients and also maintain a supportive and caring team-based environment.

Through my research, I want to improve allogeneic hematopoietic cell transplantation for patients with primary immunodeficiencies. I’m also working to improve the treatment of patients with X-linked inhibitor of apoptosis (XIAP) deficiency and hemophagocytic lymphohistiocytosis (HLH).

In my free time, I like to play the piano, bake and spend time with my family.

BS: University of Tennessee, Knoxville, TN, 1998.

MD: Rush Medical College, Chicago, IL, 2003.

Residency: Rush University Medical Center, Chicago, IL, 2006.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008.

Services and Specialties

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, 22Q-VCFS, Hemophagocytic lymphohistiocytosisHLH, Rare Lung Diseases

Research Areas

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Grom, AA; Canna, SW; Abu-Arja, RF; Sinha, R; Peixoto, L; Cannizzaro, E; Chandrakasan, S; Driest, K; Marsh, R; Neven, B; et al. Pediatric Rheumatology Online Journal. 2024; 21:86.

Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity. Fitch, T; Lane, A; McDonnell, J; Bleesing, J; Jordan, M; Kumar, A; Khandelwal, P; Khoury, R; Marsh, R; Chandra, S. Transplantation and cellular therapy. 2024; 30:101.e1-101.e12.

Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study. Eissa, H; Thakar, MS; Shah, AJ; Logan, BR; Griffith, LM; Dong, H; Parrott, RE; O'Reilly, RJ; Dara, J; Kapoor, N; et al. Journal of Allergy and Clinical Immunology. 2024; 153:287-296.

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Leiding, JW; Arnold, DE; Parikh, S; Logan, B; Marsh, RA; Griffith, LM; Wu, R; Kidd, S; Mallhi, K; Chellapandian, D; et al. Blood. 2023; 142:2105-2118.

Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease. Chandrasekaran, P; Han, Y; Zerbe, CS; Heller, T; DeRavin, SS; Kreuzberg, SA; Marciano, BE; Siu, Y; Jones, DR; Abraham, RS; et al. Journal of Allergy and Clinical Immunology. 2023; 152:1619-1633.e11.

The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; et al. Arthritis and Rheumatology. 2023; 75:1714-1732.

The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; et al. Annals of the Rheumatic Diseases. 2023; 82:1271-1285.

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Geerlinks, AV; Scull, B; Krupski, C; Fleischmann, R; Pulsipher, MA; Eapen, M; Connelly, JA; Bollard, CM; Pai, S; Duncan, CN; et al. Blood Advances. 2023; 7:3725-3734.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Hines, MR; Knight, TE; McNerney, KO; Leick, MB; Jain, T; Ahmed, S; Frigault, MJ; Hill, JA; Jain, MD; Johnson, WT; et al. Transplantation and cellular therapy. 2023; 29:438.e1-438.e16.

Outcomes among racial and ethnic minority groups with X-linked agammaglobulinemia from the USIDNET registry. O'Toole, D; Groth, D; Wright, H; Bonilla, FA; Cunningham-Rundles, C; Sullivan, KE; Ochs, HD; Marsh, RA; Feuille, E; Fuleihan, RL. Journal of Allergy and Clinical Immunology: In Practice. 2023; 11:1945-1946.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating